AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

The contest for gentailers isn’t electrons – it’s politics
Markets

The contest for gentailers isn’t electrons – it’s politics

Big spend, high stakes: gentailers outline plans that depend on political tolerance.

Air NZ’s Ravishankar grows up in public
Opinion

Pattrick Smellie: Air NZ’s Ravishankar grows up in public

The national airline’s new CEO faces plenty of challenges, some self-inflicted.

Scam protection at heart of Code of Banking Practice update
Finance

Scam protection at heart of Code of Banking Practice update

Compensation is on the cards if banks fail all five scam-protection commitments.

RBNZ staff thin on ground after asbestos reopen
Finance

RBNZ staff thin on ground after asbestos reopen

The finance minister understands the new flexible working policy for the RBNZ is near.